131I-rituximab

DRUG3 trials

Sponsors

Korea Cancer Center Hospital

Conditions

Relapsed or Refractory Diffuse Large B Cell LymphomaRelapsed or Refractory Follicular Lymphoma or Mantle Cell LymphomaRelapsed or Refractory Marginal Zone B-cell Lymphoma

Phase 2

A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Korea Cancer Center HospitalRelapsed or Refractory Diffuse Large B Cell Lymphoma

Start: 2012-06-30End: 2017-06-30Target: 24Updated: 2012-11-14

131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Korea Cancer Center HospitalRelapsed or Refractory Marginal Zone B-cell Lymphoma

Start: 2011-10-31End: 2016-09-30Target: 28Updated: 2012-09-05

131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma

Korea Cancer Center HospitalRelapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma

Start: 2012-06-30End: 2017-06-30Target: 29Updated: 2012-09-05